NAFLD: Reporting Histologic Findings in Clinical Practice

Elizabeth M. Brunt, David E. Kleiner, Danielle H. Carpenter, Mary Rinella, Stephen A. Harrison, Rohit Loomba, Zobair Younossi, Brent A. Neuschwander‐Tetri, Arun J. Sanyal, for the American Association for the Study of Liver Diseases NASH Task Force – 27 October 2020 – The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical need it presents. Drug development and clinical trials are rapidly growing, as are noninvasive tests for markers of steatosis, inflammation, injury, and fibrosis.

The Impact of Dabigatran Treatment on Sinusoidal Protection Against Hepatic Ischemia/Reperfusion Injury in Mice

Daisuke Noguchi, Naohisa Kuriyama, Taemi Hibi, Koki Maeda, Toru Shinkai, Kazuyuki Gyoten, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, Masashi Kishiwada, Hiroyuki Sakurai, Shugo Mizuno – 27 October 2020 – Thrombin is a key player in the coagulation cascade, and it is attracting much attention as a promotor of cellular injured signaling. In ischemia/reperfusion injury (IRI), which is a severe complication of liver transplantation, thrombin may also promote tissue damage.

The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States

Lisa M. Nyberg, T. Craig Cheetham, Heather M. Patton, Su‐Jau Yang, Kevin M. Chiang, Susan L. Caparosa, Julie A. Stern, Anders H. Nyberg – 24 October 2020 – Nonalcoholic fatty liver disease (NAFLD) is a global public health problem. However, the natural history of NAFLD is incomplete. This is a retrospective cohort study of patients identified with NAFLD by diagnosis codes in a large, community‐based health care delivery system.

Liver Transplantation Using Hepatitis C Virus–Viremic Donors Into Hepatitis C Virus–Aviremic Recipients as Standard of Care

Humberto Bohorquez, Emily Bugeaud, Natalie Bzowej, Jennifer Scheuermann, Jonathan Hand, David Bruce, Ian Carmody, Ari Cohen, Shobha Joshi, John Seal, Dennis Sonnier, George Therapondos, Nigel Girgrah, Stephanie Anders, George E. Loss – 24 October 2020 – Liver transplantation (LT) using allografts from hepatitis C virus (HCV)‐viremic/nucleic acid testing–positive donors’ (DNAT+) organs into HCV‐aviremic recipients (rHCV−) has been limited owing to nearly universal HCV transmission and concerns regarding availability, safety, and efficacy post‐LT with direct‐acting antiviral (DAA) therapy.

Triple‐Phase Computed Tomography May Replace Dual‐Energy X‐ray Absorptiometry Scan for Evaluation of Osteoporosis in Liver Transplant Candidates

Manhal Izzy, Benyam D. Addissie, Juan Pablo Arab, Moira B. Hilscher, Amanda Cartee, David C. Lee, Yong Lee, Joel G. Fletcher, Tony M. Keaveny, William Sanchez – 23 October 2020 – Assessment of bone density is an important part of liver transplantation (LT) evaluation for early identification and treatment of osteoporosis. Dual‐energy X‐ray absorptiometry (DXA) is currently the standard clinical test for osteoporosis; however, it may contribute to the appointment burden on LT candidates during the cumbersome evaluation process, and there are limitations affecting its accuracy.

Subscribe to